Tevogen Bio Holdings Inc. (TVGN) NASDAQ
7.16
+0.16(+2.29%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
7.16
+0.16(+2.29%)
Currency In USD
| Previous Close | 7 |
| Open | 7.51 |
| Day High | 9 |
| Day Low | 6.74 |
| 52-Week High | 75.5 |
| 52-Week Low | 4.14 |
| Volume | 65,442.85 |
| Average Volume | 29,702 |
| Market Cap | 29.98M |
| PE | -0.89 |
| EPS | -8.08 |
| Moving Average 50 Days | 6.58 |
| Moving Average 200 Days | 23.63 |
| Change | 0.16 |
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
GlobeNewswire Inc.
Mar 11, 2026 7:15 PM GMT
Tevogen: Long COVID Awareness Month Tevogen: Long COVID Awareness Month WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today issued a statement from Founder and CEO Dr. Ryan Saa
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
GlobeNewswire Inc.
Mar 09, 2026 11:45 AM GMT
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified g
Letter to Shareholders from CEO Dr. Ryan Saadi
GlobeNewswire Inc.
Mar 06, 2026 8:40 PM GMT
WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). Dear Shareholders, As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, revenue-generating healthc